CHNQD-02204
CHNQD-02204 is a potent and selective antifungal agent with in vitro activity against Candida albicans, with a MIC of 0.025 μg/mL. CHNQD-02204 inhibits ergosterol biosynthesis, disrupts the membrane integrity and biofilm formation of Candida albicans, and suppresses the morphological transition of Candida albicans from yeast to hyphal form. CHNQD-02204 can be used in studies related to candidal infections.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 3094676-22-6
- Formel: C25H18Cl2O8
- Molecular Weight:517.31
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Protokoll
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
In Vitro
CHNQD-02204 (0.05 μg/mL; 2 h) disrupts the cell surface integrity of Candida albicans ATCC 10231, leading to cell shrinkage and indentation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
| Species | Dose | Route | T1/2 | Tmax | Cmax | AUC0-t | AUC0-∞ | CL |
|---|---|---|---|---|---|---|---|---|
| Rat[1] | 2.5 mg/kg | i.v. | 12.7 min | 1 min | 5952.5 ng/mL | 31896.7 min·ng/mL | 46463.1 min·ng/mL | 53.8 mL/min/kg |
In Vivo
CHNQD-02204 (2.5 mg/kg; intravenous injection; twice daily; for 3 consecutive days) reduces the fungal burden in the spleen, lung and kidney of immunocompromised mice with disseminated candidiasis, and alleviates infection-induced body weight loss[1].
CHNQD-02204 (10 mg/kg; intravenous injection; single administration) is well tolerated in healthy female C57BL/6J mice, with no mortality, body weight changes or histopathological abnormalities observed within 7 days[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR (female, 6-week-old, 24-26 g, immunocompromised via intraperitoneal cyclophosphamide injection)[1]
-
Dosage:2.5 mg/kg
-
Administration:i.v.; three doses at 2, 6, and 10 h post-infection
-
Result:Reduced fungal burden in the spleen by 0.40 log10 CFU compared with the infected control group.
Reduced fungal burden in the lung by 0.29 log10 CFU compared with the infected control group.
Reduced fungal burden in the kidney by 0.62 log10 CFU compared with the infected control group.
-
Animal Model:ICR (female, 6-week-old, 24-26 g, immunocompromised via intraperitoneal cyclophosphamide injection)[1]
-
Dosage:2.5 mg/kg
-
Administration:i.v.; twice daily; 3 consecutive days
-
Result:Reduced fungal burden in the spleen by 0.37 log10 CFU compared with the infected control group.
Reduced fungal burden in the lung by 0.78 log10 CFU compared with the infected control group.
Reduced fungal burden in the kidney by 0.41 log10 CFU compared with the infected control group.
Marked reduction of fungal content in multiple organs, with almost no fungal growth observed in the lungs via periodic acid-Schiff staining.
Mitigated weight loss induced by fungal infection during the 3-day treatment period.
Chemical Information
-
CAS. Nr. 3094676-22-6
-
Molecular Weight 517.31
-
Formel C25H18Cl2O8
-
SMILES
ClC(C=CC=C1)=C1C(OC2=C(Cl)C=CC=C2C3=C(OC)C(C4=C(O)C=C(OC)C(OC)=C4O3)=O)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
CHNQD-02204 Related Classifications
HY-183333 Related Classifications
Powered by Bioz